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Abstract
Background:Metaplastic breast cancer is one of the most therapeutically challenging forms of breast cancer because of its
highly heterogeneous and chemoresistant nature. We have previously demonstrated that ribosomal protein L39 (RPL39) and its
gain-of-function mutation A14V have oncogenic activity in triple-negative breast cancer and this activity may be mediated
through inducible nitric oxide synthase (iNOS). The function of RPL39 and A14V in other breast cancer subtypes is currently
unknown. The objective of this study was to determine the role and mechanism of action of RPL39 in metaplastic breast
cancer.
Methods: Both competitive allele-specific and droplet digital polymerase chain reaction were used to determine the RPL39
A14Vmutation rate in metaplastic breast cancer patient samples. The impact of RPL39 and iNOS expression on patient over-
all survival was estimated using the Kaplan-Meier method. Co-immunoprecipitation and immunoblot analyses were used for
mechanistic evaluation of RPL39.
Results: The RPL39 A14Vmutation rate was 97.5% (39/40 tumor samples). High RPL39 (hazard ratio ¼ 0.71, 95% confidence
interval ¼ 0.55 to 0.91, P¼ .006) and iNOS expression (P¼ .003) were associated with reduced patient overall survival. iNOS
inhibition with the pan-NOS inhibitor NG-methyl-L-arginine acetate decreased in vitro proliferation andmigration, in vivo
tumor growth in both BCM-4664 and BCM-3807 patient-derived xenograft models (P¼ .04 and P¼ .02, respectively), and
in vitro and in vivo chemoresistance. Mechanistically, RPL39 mediated its cancer-promoting actions through iNOS signaling,
which was driven by the RNA editing enzyme adenosine deaminase acting on RNA 1.
Conclusion: NOS inhibitors and RNA editing modulators may offer novel treatment options for metaplastic breast cancer.
Metaplastic breast carcinoma is a rare form of breast cancer, ac-
counting for 0.2% to 5% of all breast cancers (1). However, it is
one of the most chemotherapy-refractory breast cancer sub-
types and is associated with a higher rate of recurrence and
poorer overall survival (OS) (2). Metaplastic breast cancers ex-
hibit diversity in their carcinomatous and sarcomatous fea-
tures, heterologous elements, and histologic and stromal
appearance (2–15). This diversity makes it a difficult disease to
treat.
Metaplastic breast cancers remain a therapeutic dilemma
primarily due to our limited understanding of its pathogenesis.
Treatment guidelines for metaplastic breast cancer are yet to be
established, and currently treatment is similar to basal-like tri-
ple-negative breast cancers (TNBCs) (16). Metaplastic breast
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cancers express several markers associated with basal-like can-
cers (eg, epidermal growth factor receptor and cytokeratin 5/6);
however, unlike basal-like carcinomas, they are typically che-
moresistant (17–19). Three-year survival rates are approxi-
mately 40% for node-positive patients compared with
approximately 70% for basal-like TNBCs (15). Node-positive pa-
tients have poorer clinical outcome, with recurrence patterns
tending to favor pulmonary metastasis (2). Using integrated
genomics and proteomics approaches, metaplastic breast can-
cers were found to be closely related to the claudin-low breast
cancer subtype (20). Claudin-low breast cancer is characterized
by the loss of cell-cell adhesion genes (5). Compared with other
breast cancer subtypes, metaplastic breast cancers and claudin-
low breast cancers are enriched for stem cell–like and epithe-
lial-to-mesenchymal transition (EMT) characteristics (20,21),
which partially contribute to their chemoresistance. A better
understanding of the molecular mechanisms underlying meta-
plastic breast cancer pathogenesis is essential to the discovery
of novel therapeutic targets for treatment.
We recently identified a novel cancer gene, ribosomal protein
L39 (RPL39), responsible for stem cell self-renewal, treatment re-
sistance, and lung metastasis in TNBC (22). Mechanistically,
RPL39 increased inducible nitric oxide synthase (iNOS)-medi-
ated nitric oxide (NO) production (22). Furthermore, the RPL39
A14V mutation was found to be a predictor of early distant
metastatic relapse to the lung and worse OS. Although RPL39
plays a critical role in TNBC, the function of this protein in other
breast cancer subtypes is currently unknown. As metaplastic
breast cancers display stem-like and EMT features, we investi-
gated the role and mechanism of action of RPL39 in this breast
cancer subtype using patient samples and in vitro and in vivo
models.
Methods
Mutation Analysis
Previously identified RPL39 gene mutations were analyzed in
tissues samples from 40 patients with pathologically confirmed
metaplastic breast cancer. Genomic DNA isolated from patient
tissue samples was analyzed for the presence of wild-type or
mutant allele using a custom-designed competitive allele-
specific TaqMan (CAST) polymerase chain reaction (PCR) assay
(Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer’s instructions. The results of the CAST PCR ana-
lysis were confirmed by droplet digital PCR (ddPCR). ddPCR was
performed using a standard protocol with custom RPL39 (A14V)
ddPCR probes and primers (Bio-Rad Laboratories, Hercules, CA)
as detailed in the Supplementary Methods (available online).
For all experiments, positive, negative, and no template controls
were used in the pre-amplification and ddPCR steps. Wild-type
RPL39 plasmid DNA was used as negative control to determine
the cutoff for RPL39 A14V mutation.
Bioinformatics Analysis
The Kaplan-Meier plotter is capable of assessing the effect of 54
675 genes on survival using 10 188 cancer samples. These in-
clude 4142 breast, 1648 ovarian, 2437 lung, and 1065 gastric can-
cer patients with a mean follow-up of 69, 40, 49, and 33 months,
respectively (24). Written informed consent was obtained from
all study patients. The primary purpose of the tool is a meta-
analysis-based biomarker assessment, and we used this for
determining the impact of RPL39 on TNBC patient survival.
Additionally, we used the Susan G. Komen foundation sequence
database for normal breast tissue from the Susan G. Komen for
the Cure Tissue Bank at Indiana University. The BAM files of
twenty normal breast tissue samples were analyzed using
Rsamtools pileup (25) within R (R Development Core Team)
using the PileupParam of min base quality ¼ 20 (Supplementary
Table 1, available online) (26).
Immunoblot Analysis
Immunoblot analyses are detailed in the Supplementary
Methods (available online).
Animal Studies
All animal studies were performed in accordance with our insti-
tutional animal use committee guidelines and are detailed in
the Supplementary Methods (available online).
Statistical Analysis
Patient and tumor characteristics were summarized using de-
scriptive statistics.
Association of patient OS with RPL39 A14V mutation status
and iNOS expression level was determined using log-rank tests.
OS was estimated using the Kaplan-Meier method, and differ-
ences were compared using the log-rank test. Fisher’s exact test
was used for bivariate analysis of categorical factors. Pairwise
differences in fractional abundance were analyzed with the
Wilcoxon rank-sum test. The correlations between biomarkers
and their statistical significance were assessed using Pearson’s
correlation coefficient and Student’s t distribution, respectively.
For the animal studies, sample means and 95% confidence
intervals (CIs) calculated as the mean plus or minus 1.96 times
the standard error of the mean, which is equivalent to the 95%
confidence interval, were plotted to visualize changes in tumor
volume over time. Differences in tumor volume were compared
using mixed-effects linear models that included a random sub-
ject effect with a heterogeneous autoregressive variance-
covariance structure to account for intra-animal correlation
across time points. The models contained fixed effects for treat-
ment, time point, and the interaction of these main effects.
Satterthwaite’s method was used to calculate the denominator
degrees of freedom for the F-tests of the fixed and simple effects
in order to account for the variance heterogeneity. For prolifer-
ation, migration, and apoptosis assays, the Student’s t test or
one-way analysis of variance (ANOVA) was used to compare
group differences. For all analyses, a two-tailed P value of less
than .05 was considered statistically significant.
In Vitro Cellular Analyses
Cell proliferation, cellular nitrate, and nitrite, migration, and
immunoprecipitation assays were performed as described in
the Supplementary Methods (available online).
Immunohistochemistry
Immunohistochemical analyses are detailed in the Supplementary
Methods (available online).
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Results
Prevalence of RPL39 A14V Mutation in Metaplastic
Breast Cancer
Utilizing a published database of 457 TNBC patients (24), we
found that high RPL39 expression was directly correlated with
reduced OS (hazard ratio ¼ 0.71, 95% confidence interval [CI] ¼
0.55 to 0.91, P¼ .006) (Figure 1A). CAST PCR and ddPCR were
used to determine RPL39 A14V mutation rate and fractional
abundance in tumor samples from patients with histologically
confirmed metaplastic breast cancer (n¼ 40) and basal-like
TNBC (n¼ 40) and available clinical outcome data. RPL39 A14V
mutation rate (97.5% [39/40] vs 0% [0/40]; Fisher’s exact test, P <
.001) (Figure 1B) and fractional abundance (Wilcoxon rank-sum
test, P¼ .03) (Figure 1C) were statistically significantly higher in
metaplastic breast cancer compared with basal-like TNBC. To
ensure that the metaplastic breast cancer patient cohort was
not skewing the data, the frequency of common mutations
identified in TNBC was evaluated. Phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha H1047R and E545K
mutations were present in 10% (4/40) of primary TNBCs and
17.5% (7/40) of metaplastic breast cancers, which is consistent
with previously published rates (20). Together, these findings
demonstrate the high prevalence of RPL39 A14V mutation in
metaplastic breast cancer.
Next, to confirm that the RPL39 A14V mutation was not a
single-nucleotide polymorphism (SNP), RNA deep sequencing
analysis was performed on 20 normal breast tissues. Results,
presented as total counts for specified nucleotides within each
sample (Supplementary Table 1, available online), indicated
that RPL39 A14V is unlikely to be an SNP. We also analyzed the
correlation between RPL39 A14V mutation and iNOS level. The
correlation did not reach statistical significance because of the
small sample size (Supplementary Figure 1 and Supplementary
Table 2, available online). Given the rarity of metaplastic breast
cancer, sufficient patient samples to accurately assess the cor-
relation between RPL39 A14V mutation and iNOS level would be
difficult to obtain.
Correlation of iNOS level With OS in Metaplastic Breast
Cancer
We previously reported that RPL39 regulates iNOS expression in
TNBC (22) and downregulation of iNOS signaling reduces tumor
growth (27). We and others have also reported that high iNOS
expression level is associated with worse survival in TNBC pa-
tients (27,28). iNOS levels were immunohistochemically eval-
uated in the same cohort of metaplastic breast cancer patient
tumor samples used for RPL39mutation analysis. OS was statis-
tically significantly shorter for metaplastic breast cancer pa-
tients in the high iNOS expression group compared with those
in the low iNOS expression group (log-rank test, P¼ .003) (Figure
2). These results indicate that increased iNOS expression is a
poor prognostic indicator in metaplastic breast cancer.
Effect of iNOS Inhibition on Metaplastic Breast
Cancer Cell Proliferation and Migration
To determine the functional relevance of iNOS, the metaplastic-
like breast cancer cell lines HS578T and BT549 were treated with
the pan-NOS inhibitor NG-methyl-L-arginine acetate (L-NMMA)
(27). The HS578T and BT549 cell lines have been reported to
possess metaplastic genotypic characteristics (23) and do not
carry the RPL39 A14V mutation. L-NMMA-mediated iNOS inhib-
ition statistically significantly reduced cell proliferation and mi-
gration in a dose-dependent manner in both cells lines (one-
way ANOVA, P¼ .04 and P¼ .02, respectively) (Figure 3, A and B).
As metaplastic breast cancers are highly chemoresistant, we
investigated whether L-NMMA increases the sensitivity of
HS578T and BT549 cells to docetaxel. Compared with vehicle
control cells, L-NMMA alone did not statistically significantly in-
crease the number of apoptotic cells (Figure 3C). However, L-
NMMA statistically significantly enhanced docetaxel-mediated
apoptosis, as evidenced by the greater number of Annexin V–
positive cells (one-way ANOVA, P¼ .03) (Figure 3C). Together,
our findings indicate that iNOS inhibition demonstrates potent
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Figure 1. RPL39 (A14V) mutation status analyzed in metaplastic breast cancer.
A) The relationship between ribosomal protein L39 (RPL39) expression and over-
all survival was assessed among 457 triple-negative breast cancer (TNBC) pa-
tients. The P value was calculated using a log-rank test. B) RPL39 A14V mutation
rate was determined by competitive allele-specific TaqMan (CAST) polymerase
chain reaction (PCR) analysis of tumor samples from patients with nonmeta-
plastic and metaplastic breast cancer (each n¼40). Fisher’s exact test was used
to compare the mutation rate in metaplastic breast cancer vs nonmetaplastic
breast cancer. PIK3CA mutations (H1047R and E545K) rates are also shown.
C) The results of the CAST PCR analysis were confirmed by droplet digital PCR.
Wilcoxon rank-sum test was used to determine statistically significant differ-
ences in the fractional abundance of the RPL39 A14V mutation between meta-
plastic breast cancer and TNBC. We used a threshold of 0.1% fractional
abundance to define low RPL39 expression level. All statistical tests were two-
sided. CI ¼ confidence interval; HR ¼ hazard ratio; MBC ¼ metaplastic breast
cancer; TNBC ¼ triple-negative breast cancer.
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anticancer effects and decreases chemoresistance in metaplas-
tic breast cancer cells. Additionally, we analyzed the effect of
iNOS inhibition on RPL39 expression and found that RPL39 ex-
pression was reduced by both L-NMMA and iNOS siRNA
(Supplementary Figure 2, available online).
Effect of RPL39 on the In Vivo Response to L-NMMA in
Metaplastic Breast Cancer
To investigate the effect of RPL39 on the in vivo response to
L-NMMA, we used RPL39 A14V mutation–positive (BCM-4664)
and –negative (BCM-3807) metaplastic breast cancer patient-
derived xenografts (PDXs). Despite the difference in RPL39muta-
tion status, both BCM-4664 and BCM-3807 tumors showed high
iNOS expression levels. L-NMMA statistically significantly
reduced tumor volume in both the BCM-4664 and BCM-3807
models compared with the vehicle control (F-tests, P¼ .04 and
P¼ .02, respectively) (Figure 4A). Compared with vehicle,
L-NMMA substantially reduced iNOS expression in both the
BCM-4664 and BCM-3807 models, verifying target engagement
(Figure 4B). Furthermore, L-NMMA in combination with doce-
taxel statistically significantly reduced tumor volume in the
BCM-4664 model compared with docetaxel alone (F-test,
P¼ .007) (Figure 4C). As BCM-3807 is highly chemosensitive,
combination effects were not observed (Supplementary Figure 3,
available online). These findings suggest that iNOS-expressing
metaplastic breast cancers are responsive to iNOS inhibition with
L-NMMA regardless of RPL39 mutation status and mechanisms
other than RPL39 A14Vmutationmay regulate iNOS expression.
Determination of RPL39 Signal Transduction Pathway
in Metaplastic Breast Cancer
As our data indicate a role of RPL39 and iNOS in metaplastic
breast cancer, we investigated the linking pathways using in sil-
ico data analysis (ingenuity pathway analysis) (Supplementary
Figure 4, available online). Ingenuity pathway analysis identi-
fied a signaling pathway linking iNOS to ubiquitin C (UBC) and
adenosine deaminase acting on RNA 1 (ADAR1). UBC is a
ubiquitin-encoding gene that has been implicated in DNA repair
and NOS signaling. The RNA-editing protein ADAR1 has re-
cently been reported to play a role in cancer stem cell (CSC) self-
renewal and to be associated with signal transducer and activa-
tor of transcription 3 (STAT3) pathway activation. Based on the
results of the pathway analysis, we hypothesized that UBC may
bind to both ADAR1 and RPL39 to activate iNOS signaling (Figure
5A). To investigate the in vivo interactions among these pro-
teins, immunoblot analysis and co-immunoprecipitation assays
were performed. Both RPL39 overexpression and A14V mutation
increased ADAR1 and phosphorylated STAT3 expression (Figure
5B). Co-immunoprecipitation with anti-UBC revealed that UBC
directly interacts with ADAR1 and RPL39 (Figure 5C), whereas
co-immunoprecipitation with anti-ADAR1 showed that ADAR1
interacted with UBC but not RPL39 (Figure 5D). These data
Figure 2. Correlation between inducible nitric oxide synthase (iNOS) expression and patient overall survival in metaplastic breast cancer. iNOS expression levels were
evaluated by immunohistochemical analysis in a cohort of metaplastic breast cancer patient tumor samples (n¼40). The graph presents Kaplan-Meier estimated
survival curves for the high and low iNOS expression groups. A two-sided log-rank test was used to determine the statistical significance of the observed difference in
survival. iNOS ¼ inducible nitric oxide synthase.
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Figure 3. Role of inducible nitric oxide synthase (iNOS) inhibition in metaplastic breast cancer cell proliferation and migration in vitro. A)Metaplastic breast cancer cell
lines HS578T and BT549 were treated with vehicle control or the indicated concentrations of L-NMMA for 72hours. Proliferation was assessed by WST1 assay (HS578T:
mean ¼ 0.76, SD ¼ 0.03, P¼ .04; BT549: mean ¼ 0.74, SD¼0.01, P¼ .04). B)Migration by scratch assay was determined in HS578T and BT549 cells treated with vehicle con-
trol or 1mM L-NMMA for 72hours. (HS578T: mean ¼ 12, SD¼1.5, P¼ .02; BT549: mean ¼ 24, SD¼3.4, P¼ .02). C) HS578T and BT549 cells were treated with vehicle con-
trol, L-NMMA alone (1mM), docetaxel alone (1nM), or combined docetaxel and L-NMMA for 72hours and the number of apoptotic cells determined by Annexin V
staining (docetaxel vs combination therapy, HS578T, mean ¼ 23.8, SD¼4.1, P¼ .03; BT549 mean ¼ 22.1, SD¼1.8, P¼ .03). Data presented are based on three independent
experiments, and error bars represent the standard deviation. P values were calculated using one-way analysis of variance, followed by the Tukey test for pairwise
comparisons. All statistical tests were two-sided.
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suggest an intermediary role for UBC in the RPL39 and ADAR1
interaction.
Next, we deciphered the sequence of signaling events acti-
vated by RPL39. To further investigate the association between
RPL39 and UBC, immunoblot analysis of RPL39-overexpressing
and RPL39 siRNA-treated HS578T and BT549 cells was per-
formed. RPL39 overexpression increased UBC expression in both
BT549 and HS578T cells (Figure 5E). siRNA-mediated RPL39
downregulation decreased UBC expression in the BT549, but not
the HS578T, cell line (Figure 5E). Changes in UBC expression
mirrored those in iNOS expression (Figure 5E). We also tested
the effect of RPL39 on ADAR1 expression. RPL39 overexpression
and A14V mutation increased the expression of ADAR1 and
phosphorylated STAT3 in HS578T and BT549 cells (Figure 5B).
Furthermore, siRNA-mediated RPL39, but not iNOS, knockdown
reduced ADAR1 expression in RPL39-overexpressing HS578T
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Figure 4. Testing the impact of inducible nitric oxide synthase (iNOS) inhibition on in vivo tumor growth and chemoresistance in metaplastic breast cancer. A) The ef-
fect of iNOS inhibition on in vivo tumor growth was determined using two metaplastic breast cancer patient-derived xenograft models, BCM-4664 and BCM-3807. Mice
(n¼10 per group) were treated with vehicle (saline, intraperitoneal [i.p.], daily) or L-NMMA (200mg/kg, i.p., daily) for 28 days. Tumor volume was measured twice
weekly. P values were calculated using Student’s t test. Data are presented as the mean, with the error bars representing 95% confidence intervals (1.96SEM). B) Target
engagement was verified by immunohistochemical analysis of iNOS expression in L-NMMA-treated BCM-4664 and BCM-3807 tumors. C) BCM-4664 mice were treated
with docetaxel alone (20mg/kg, i.p., once every 14 days) or in combination with L-NMMA for 42 days. Tumor volume was measured twice weekly. Data were analyzed
using Student’s t test and presented as the mean 6 95% confidence interval (1.96 SEM). All statistical tests were two-sided.
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Figure 5. Signal transduction pathway of RPL39 in metaplastic breast cancer. A) Ingenuity pathway analysis was done to identify potential links between RPL39 and
iNOS. B) Immunoblot analysis of ADAR1 and phosphorylated STAT3 was performed in HS578T and BT549 cells transfected with a plasmid to overexpress RPL39 or
RPL39 A14V. C) Ubiquitin C (UBC) was immunoprecipitated from HS578T and BT549 cell extracts. Immunoprecipitates were immunoblotted to detect the presence of
the indicated proteins. D) ADAR1 was immunoprecipitated from HS578T and BT549 cell extracts. Immunoprecipitates were immunoblotted to detect the presence of
the indicated proteins. E) Immunoblot analysis was performed to determine the expression of UBC, iNOS, and RPL39 in RPL39-overexpressing and siRNA-treated
HS578T and BT549 cells. F) Immunoblot analysis was performed to determine the expression of iNOS, ADAR1, and phosphorylated STAT3 in iNOS and RPL39 in RPL39-
overexpressing HS578T and BT549 cells treated with RPL39 or iNOS siRNA. G) Schematic of the proposed RPL39/UBC/ADAR1/iNOS/STAT3 signaling pathway is shown.
b-actin served as a loading control in (B–F). ADAR1 ¼ adenosine deaminase acting on RNA 1; IB ¼ immunoblot; iNOS ¼ inducible nitric oxide synthase; IP ¼ immunopre-
cipitate; p ¼ phosphorylated; RPL39 ¼ ribosomal protein L39; STAT3 ¼ signal transducer and activator of transcription 3; UBC ¼ ubiquitin C.
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and BT549 cells, suggesting that ADAR1 is downstream of RPL39
and upstream of iNOS (Figure 5F). Furthermore, siRNA-
mediated RPL39 and iNOS knockdown reduced phosphorylated
STAT3 expression, suggesting that STAT3 is downstream of
ADAR1 and iNOS (Figure 5F). A schematic of the proposed RPL39
signaling pathway is shown in Figure 5G. These data indicate
that the RNA-editing enzyme ADAR1 drives iNOS signaling and
a STAT3-dependent signaling pathway in metaplastic breast
cancer.
Role of RPL39 in Metaplastic Breast Cancer Cell
Proliferation and Migration
Whole-exome sequencing has previously shown the greatest
fold-changes in RNA editing frequency in specific loci of CSCs
(29). These sites were located within transcripts of the cytidine
deaminase apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3D (APOBEC3D); GLI family zinc finger 1(GLI1);
antizyme inhibitor 1 (AZIN1); and ubiquitin ligase human homo-
log of mouse double minute 2 (MDM2). Analysis of editing rates
from the RNA-seq data set showed increased RNA editing of
APOBEC3D, and GLI1, AZIN1, andMDM2 in CSCs (29). RNA editing
site-specific quantitative PCR also revealed increased RNA edit-
ing of APOBEC3D, GLI1, AZIN1, and MDM2 transcripts in lentivi-
ral ADAR1-expressing cells (29).
As RPL39 increases ADAR1 expression, we investigated the
role of RPL39 in the RNA editing of these genes. Overexpression
of RPL39 in HS578T and BT549 cell lines statistically significantly
increased the edited forms of APOBC3D, GLI1, and AZN1 RNA
(Figure 6, A and B), but not MDM2 (data not shown), further con-
firming a role for RNA editing in the RPL39-mediated signaling
pathway in metaplastic breast cancer.
To determine whether RPL39-mediated iNOS signaling is
modulated by ADAR1, iNOS expression was determined in
RPL39-overexpressing HS578T and BT549 cells treated with
ADAR1-specific siRNA. ADAR1 knockdown inhibited iNOS, but
not RPL39, expression (Figure 6C), indicating that ADAR1 is
downstream of RPL39 and upstream of iNOS. UBC expression
was unaffected by ADAR1 knockdown, suggesting that UBC acts
as bridge between RPL39 and ADAR1 rather than having a direct
functional role. Additionally, ADAR1 knockdown affected cell
migration (Figure 6D) and proliferation (Figure 6E) in RPL39-
overexpressing cells. Together, these results indicate that RPL39
signals through an ADAR1/iNOS/STAT3 pathway in metaplastic
breast cancer.
Discussion
Metaplastic breast cancer is an exceedingly rare, highly lethal,
and chemotherapy-resistant TNBC (30). Targeted therapies for
metaplastic breast cancer are currently not available; therefore,
understanding the molecular mechanisms underlying its
tumorigenesis is key to developing effective therapies.
Hennesey et al. (21) demonstrated that metaplastic breast
cancer tumors were phenotypically similar to claudin-low sub-
type, with an increased CSC component (20). Thus, we hypothe-
sized that mutations previously described in CSCs may play a
pivotal role in metaplastic breast cancer. In the present study,
we found that the prevalence of the RPL39 A14V mutation is
nearly ubiquitous in metaplastic breast cancer. High cytoplas-
mic iNOS level was associated with statistically significantly
worse OS in patients with metaplastic breast cancer. These data
provide evidence that iNOS is a valid therapeutic target for
metaplastic breast cancer.
Previously, we identified the RPL39 A14V mutation in TNBC
cells and found that it conferred a growth advantage (22).
Additionally, RPL39 knockdown reduced the number of CD44þ/
CD24-/low and tumor-initiating cells, mammosphere formation
efficiency, and lung metastases (22). Mechanistically, RPL39
increased iNOS-mediated NO production (22). High iNOS expres-
sion was associated with worse survival in patients with basal-
like TNBC (27). Importantly, we demonstrated that L-NMMA-
mediated iNOS inhibition suppressed TNBC tumorigenicity by
decreasing proliferation, CSC self-renewal, and migration (27).
In the present study, we found that iNOS inhibition with L-
NMMA statistically significantly decreased proliferation and mi-
gration in vitro and statistically significantly enhanced
docetaxel-mediated apoptosis in vitro in the metaplastic-like
breast cancer cell lines HS578T and BT549. Our in vitro findings
were corroborated in vivo. L-NMMA statistically significantly
reduced tumor volume in the BCM-4664 (RPL39 A14V mutation–
positive) and BCM-3807 (RPL39 A14V mutation–negative) meta-
plastic PDXs. Together, our in vitro and in vivo findings indicate
that L-NMMA may be an effective therapeutic option for meta-
plastic breast cancer. L-NMMA decreased tumor volume in
metaplastic PDXs regardless of RPL39 mutational status, sug-
gesting that high iNOS expression in metaplastic breast cancer
may be dependent on RPL39-independent pathways.
Our study is not without limitations. The number of patient
samples in the study was small primarily because of the rarity
of the disease. The small sample size prevented accurate ana-
lysis of the correlation of RPL39 and iNOS expression with sur-
vival. Furthermore, the impact of RPL39 on the iNOS-mediated
NO pathway was limited to the in vitro analysis of cellular ni-
trate and nitrite levels. In vivo biophysical analysis of NO me-
tabolites such as peroxinitrate, reactive nitrogen species, and
reactive oxygen species in the context of the stromal micro-
environment may provide additional mechanistic insights into
the role of NO in metaplastic breast cancer. We plan in future
studies to investigate the role of NO and related species in
metaplastic breast cancer through comprehensive analysis
involving biophysical, immunohistochemical, and mass spec-
trometric techniques.
We investigated the mechanism of action of RPL39 and iNOS
in metaplastic breast cancer using in silico data analysis (in-
genuity pathway analysis) and identified ADAR1 and UBC as im-
portant components of the RPL39/iNOS-mediated signaling
pathway in metaplastic breast cancer. ADAR1 has recently been
implicated in STAT3-dependent signaling in CSCs (29).
Figure 6. Role of RPL39 and RNA editing in metaplastic breast cancer cell proliferation and migration. A and B) RNA editing analysis is shown for ABOBEC3D, GLI1, and
AZIN1 in RPL39-overexpressing HS578T and BT549 cells (HS578T cells: ABOBEC3D, mean ¼ 16.1, SD¼2.8, P¼ .03; GLI1, mean ¼ 17.2, SD¼3.1, P¼ .04; AZIN1, mean ¼ 21.4,
SD¼ 1.8, P¼ .02) (BT549 cells: ABOBEC3D, mean ¼ 2.1, SD¼0.3, P¼ .02; GLI1, mean ¼ 1.6, SD¼0.2, P¼ .04; AZIN1, mean ¼ 1.9, SD¼ 0.2, P¼ .04). C) Immunoblot analysis
with the indicated antibodies was performed using cell lysates from RPL39-overexpressing HS578T and BT549 cells treated with ADAR1-specific siRNA. D) Migration
(P < .001) and (E) proliferation indices were measured in HS578T control cells, RPL39-overexpressing cells, and RPL39-overexpressing cells treated with ADAR1-specific
siRNA (P < .001). Error bars represent standard deviation from the mean. Two-sided Student’s t test was used to calculate the P values. ADAR1 ¼ adenosine deaminase
acting on RNA 1; APOBEC3D ¼ catalytic polypeptide-like 3D; AZIN1 ¼ antizyme inhibitor 1; GLI1 ¼ GLI family zinc finger 1; iNOS ¼ inducible nitric oxide synthase;
MDM2 ¼mouse double minute 2; RPL39 ¼ ribosomal protein L39; UBC ¼ ubiquitin C.
A
R
T
IC
LE
9 of 10 | JNCI J Natl Cancer Inst, 2017, Vol. 109, No. 6
Downloaded from https://academic.oup.com/jnci/article-abstract/109/6/djw292/2758642
by IUPUI University Library user
on 05 January 2018
This pathway may be directly edited in the CSC self-renewal of
other cancers (29). In the present study, RNA editing was found
to play a critical role in the RPL39/iNOS-mediated signaling
pathway. Our results demonstrating the role of iNOS and RNA
editing in metaplastic breast cancer provide a meaningful ad-
vancement in the development of potential therapeutic av-
enues for this highly lethal disease. The ability of ribosomal
proteins to affect cellular translational capacity through RNA
editing is a critical avenue of research for metaplastic breast
cancer. Mutations in genes involved in ribosome function may
play a crucial role in cancer survival and may allow for the de-
velopment of novel targeted therapies for therapy-resistant
cancers.
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